李歆






专业研究方向:

药事管理、药物政策、卫生技术评估、药物经济学

 

电子邮箱:

xinli@njmu.edu.cn


个人简介:

教授,博士,博士生导师,南京医科大学药学院副院长、医政学院互聘教授,公共卫生学院全球健康中心PI,入选省333高层次人才培养工程。兼任中国研究型医院学会药物经济学专委会常务委员、江苏省卫生经济学会常务理事、《医药导报》编委、SCI期刊International Journal of Clinical Pharmacy编委、SSCI期刊Frontiers in Public Health副主编等。主持3项国家自然科学基金项目(管理学部),1项美国中华医学基金会卫生政策体系公开竞标项目(CMB-OC)、2项江苏省软科学项目和20余项政府、企业委托项目,近三年累积到账科研经费300余万元。以通讯作者在Journal of Global Health、International Journal of Cancer、International Journal for Equity in Health等SCI/SSCI/北大核心期刊上发表学术论文80余篇。主编2部学术专著、1份研究报告获得副省长批示。多次指导研究生获得国家奖学金。

  


 代表性研究课题:   

(1) 创新抗癌药物医保覆盖对癌症用药可及性与经济性的影响:价值视角下的政策评估与优化研究. 国家自然科学基金面上项目,项目批准号:72074123,负责人(经费:48万)

(2)基于AMS策略导向的医院抗菌药物管理模式构建:综合评价与准实验干预研究.国家自然科学基金面上项目,项目批准号:71673147,负责人(经费:48万)

(3)医院临床药学服务的影响因素分析与质量评价研究. 国家自然科学基金青年项目,项目批准号:71003055,负责人(经费:17万)

(4)The impact of clinical pharmacy services on the quality use of medicines in context of China’s healthcare provider payment reform: a multicenter cluster-randomized controlled trial. 美国中华医学基金会公开竞争项目(CMB-OC),负责人(经费:4万美元)

(5)带量采购政策对江苏省医药产业创新能力的影响研究. 江苏省科技厅创新支撑软科学研究项目, 项目批准号:BR2023018-5, 负责人(经费:5万)


 

代表性研究成果:

(1) Yan Jin; Hongtao Li; Pei Zhang; Man Yu; Huang Zhang; Xin Li* ; The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross-national comparison study, International Journal of Cancer, 2023, 2023(152): 2351-2361

(2) Yanyan Liu; Yuwen Bao; Yaxin Huang; Mengdie Zhang; Xin Li* ; How National Health Insurance Coverage Policy Changed the Use of Lenvatinib for Adult Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Analysis with Real World Big Data, International Journal for Equity in Health, 2023, 22(256)

(3) Ying Tao Lin; Chong Chong Zhou; Kai Xu; Mengdie Zhang; Xin Li *; Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China, Therapeutic advances in Medical Oncology, 2023, 2023(15)

(4) Yuwen Bao; Yanyan Liu; Rui Ma; Pei Zhang; Xin Li* ; The correlation between the costs and clinical

benefits of national price-negotiated anticancer drugs for specific cancers in China, Journal of Global Health, 2023, 13(04140)

(5) Lele Cai; Tiantian Tao; Hongtao Li; Zhuolin Zhang; Lingli Zhang; Xin Li* ; Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study, Journal of Global Health, 2022, 12(11016)